# UK Prospective Diabetes Study - post study monitoring (PSM) and cohort follow-up (CFU)

Submission date	Recruitment status	<ul><li>Prospectively registered</li></ul>			
17/10/2000	No longer recruiting	☐ Protocol			
Registration date	Overall study status	Statistical analysis plan			
17/10/2000	Completed	[X] Results			
Last Edited	Condition category	[] Individual participant data			
22/05/2024	Nutritional, Metabolic, Endocrine				

# Plain English summary of protocol

Not provided at time of registration

# Contact information

# Type(s)

Scientific

#### Contact name

Dr Rury R Holman

#### Contact details

Diabetes Trials Unit OCDEM, Churchill Hospital Old Road, Headington Oxford United Kingdom OX3 7LJ

# Additional identifiers

# Protocol serial number

G8109618 (now incorporates G8815630)

# Study information

#### Scientific Title

-

# Acronym

**UKPDS** 

# **Study objectives**

Please note that as of 15/08/2008 this record has been extensively updated and now includes a follow-up study. All details pertaining to these updates can be found in the relevant field under the above update date. At this time, the title of this trial was changed to the above; the previous title was: UK prospective diabetes study - post-study monitoring (PSM). Please also note that the anticipated end date of this trial was extended to 31/12/2007; the previous anticipated end date was 30/09/2002.

# Current hypothesis as of 15/08/2008:

To determine whether improved blood glucose control will prevent the complications of type 2 diabetes, and whether any mode of therapy, diet, insulin, sulphonylurea or metformin, has specific advantages or disadvantages. The trial showed that improved blood glucose and blood pressure control did lead to a reduction in the incidence of complications of type 2 diabetes. All contactable surviving patients from the trial are being followed up during the post-study monitoring and the cohort follow-up phases, to track any changes in the incidence of complications. There is no further intervention in these phases. Physicians are responsible for each patient's care. The PSM and CFU phases of the study are examining possible legacy effects 10 years post-trial of earlier randomised allocation to more intensive blood glucose and /or blood pressure control.

# Previous hypothesis:

To determine whether improved blood glucose control will prevent the complications of type 2 diabetes, and whether any mode of therapy, diet, insulin, sulphonylurea or metformin, has specific advantages or disadvantages. The trial showed that improved blood glucose and blood pressure control did lead to a reduction in the incidence of complications of type two diabetes. All contactable surviving patients from the trial are being followed up during the post-study monitoring phase, to track any changes in the incidence of complications. There is no further intervention in this phase. Physicians responsible for each patient's care.

# Ethics approval required

Old ethics approval format

# Ethics approval(s)

Ethics approval received from the South East Multi-centre Research Ethics Committee on the 20th September 2002 (MREC 02/01/85)

# Study design

Randomized controlled trial

# Primary study design

Interventional

# Study type(s)

**Not Specified** 

# Health condition(s) or problem(s) studied

Diabetes

#### **Interventions**

Diet/insulin/sulphonylurea/metformin in preventing the complications of type 2 diabetes.

### Intervention Type

Drug

#### **Phase**

Not Applicable

# Drug/device/biological/vaccine name(s)

Insulin/sulphonylurea/metformin

# Primary outcome(s)

- 1. Diabetes-related mortality: deaths from heart attacks, sudden death, stroke, complications from peripheral vascular disease or amputations, renal failure, hyperglycaemic or hypoglycaemic coma.
- 2. Total mortality
- 3. Diabetes-related mortality and major clinical endpoints, including non-fatal myocardial infarct, clinical angina with confirmatory abnormal ECG, heart failure, major stroke, retinal photocoagulation, vitreous haemorrhage, blindness, renal failure

# Key secondary outcome(s))

Added 15/08/2008:

- 1. Quality of life
- 2. Health economic outcomes
- 3. Cognitive function

# Completion date

30/09/2002

# **Eligibility**

#### Key inclusion criteria

- 1. Newly diagnosed type 2 diabetic patients
- 2. Aged 25 65 years inclusive (median age 52 years)
- 3. Two fasting plasma glucose concentrations more than 6 mmol/l

### Participant type(s)

**Patient** 

# Healthy volunteers allowed

No

# Age group

Adult

#### Lower age limit

25 years

#### Upper age limit

65 years

Sex

# Key exclusion criteria

- 1. Severe vascular disease
- 2. Accelerated hypertension
- 3. Proliferative or pre-proliferative retinopathy
- 4. Renal failure
- 5. Other life threatening diseases an illness requiring systematic steroids
- 6. An occupation that precluded insulin therapy
- 7. Language difficulties
- 8. Ketouric greater than 3 millimols per litre suggestive of insulin dependent diabetes

#### Date of first enrolment

01/03/1998

#### Date of final enrolment

30/09/2002

# Locations

#### Countries of recruitment

United Kingdom

England

# Study participating centre Diabetes Trials Unit

Oxford United Kingdom OX3 7LJ

# Sponsor information

# Organisation

Medical Research Council (MRC) (UK)

# Organisation

University of Oxford Diabetes Trials Unit

# Funder(s)

# Funder type

Industry

#### Funder Name

Medical Research Council (MRC) (UK)

# Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, MRC

# **Funding Body Type**

Government organisation

# **Funding Body Subtype**

National government

#### Location

United Kingdom

#### **Funder Name**

Several pharmaceutical companies

#### **Funder Name**

Other organisations

### **Funder Name**

For a full list of sources of funding for this trial, please visit the trial website at http://www.dtu.ox.ac.uk/ukpds/funding.php

# **Results and Publications**

Individual participant data (IPD) sharing plan

# IPD sharing plan summary

Not provided at time of registration

# **Study outputs**

Output	Details	Date	Date	Peer	Patient-
type		created	added	reviewed?	facing?
Results article	UKPDS results:	12/09 /1998		Yes	No

Results article	UKPDS results:	12/09 /1998		Yes	No
Results article	UKPDS results:	12/09 /1998		Yes	No
Results article	UKPDS results:	12/09 /1998		Yes	No
Results article	results of 10-year follow-up of intensive glucose control:	09/10 /2008		Yes	No
Results article	results of long-term follow-up after tight control of blood pressure:	09/10 /2008		Yes	No
Results article	results	05/03 /2013		Yes	No
Results article	UKPDS results	01/03 /2020	10/02 /2020	Yes	No
Results article	UKPDS 89 results	01/08 /2021	04/10 /2021	Yes	No
Results article	UKPDS 91 results	17/05 /2024	22/05 /2024	Yes	No
<u>Study</u> <u>website</u>	Study website	11/11 /2025	11/11 /2025	No	Yes